Abstract 1604P
Background
Analysis of the most common prevalent symptoms among patients with advanced cancer diagnosis is needed in order to reach the most appropriate interventions leading to improved quality of life of these patients. The aim of this study is to report on the overall symptom prevalence among patients with advanced cancer diagnosis under palliative care and to analyze the difference of symptom prevalence between elderly (≥ 65 years) and adult (<65 years) patients.
Methods
A retrospective cohort study of 400 patients with advanced cancer who were admitted under palliative care between 1st January 2017 to December 31st, 2021. Data were retrieved from electronic medical records.
Results
Anorexia (91%), fatigue (98%), drowsiness (84%) and pain (83%) were the highest 4 prevalent symptoms for the whole group, followed by depression (76%) and anxiety (72%). Adult patients had significant higher pain (80% versus 76%), depression (83% versus 68%) and anxiety (77% versus 65%), compared to elderly (≥ 65 years) patients. On multivariate analysis, pain only was significantly higher in adult patients (p=0.021). The reported percentage of symptom prevalence for the whole group is higher than that in the literature, indicating late referral to palliative care.
Conclusions
There is a high percentage of symptom prevalence among our patients and a short median overall survival that indicates late referral to palliative care. Adult patients had significantly higher pain, depression, and anxiety compared to elderly patients. An earlier integration of palliative care is recommended in the overall management of our patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05